<DOC>
	<DOCNO>NCT01793675</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( HSCT ) currently curative treatment myelodysplastic syndrome ( MDS ) , especially advanced MDS ( blast &gt; 5 % ) . However , many patient find HLA-matched donor . haploidentical donor alternative stem cell source . study hypothesis : Haploidentical/mismatched hematopoietic stem cell transplantation improve survival patient myelodysplastic syndrome</brief_summary>
	<brief_title>Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients MDS ( 1 ) intermediate2 high risk ( 2 ) low intermediate1 risk drug resistance disease progression without identical sibling donor Contraindication HSCT Pregnancy Mental illness</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>